MADISON, N.J., Jan. 11, 2017 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, announced that it will report fourth quarter and full year 2016 results on Thursday, January 26, 2017, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.
The conference call can be accessed in listen-only mode by dialing 773-681-5898, passcode 3214469. The company suggests participants dial in approximately 10 minutes before the call.
A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or by phone at 866-373-9234 for domestic callers or 203-369-0282 for international callers. Telephone replays will be available from approximately 10:30 a.m. Eastern Time on January 26, 2017 until midnight Eastern Time on February 9, 2017.
Anyone listening to the call is encouraged to read the company’s periodic reports on file with the Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.
About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world’s largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 43,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com.
Contacts:
Shawn Bevec (Investors): 973-520-2900
Dennis Moynihan (Media): 973-520-2800
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/quest-diagnostics-to-release-fourth-quarter-and-full-year-2016-financial-results-on-january-26-300389554.html
SOURCE Quest Diagnostics
